MX340168B - Polipeptidos bifuncionales. - Google Patents

Polipeptidos bifuncionales.

Info

Publication number
MX340168B
MX340168B MX2011012184A MX2011012184A MX340168B MX 340168 B MX340168 B MX 340168B MX 2011012184 A MX2011012184 A MX 2011012184A MX 2011012184 A MX2011012184 A MX 2011012184A MX 340168 B MX340168 B MX 340168B
Authority
MX
Mexico
Prior art keywords
peptide
antibody
immune effector
bifunctional polypeptides
mhc
Prior art date
Application number
MX2011012184A
Other languages
English (en)
Other versions
MX2011012184A (es
Inventor
Li Yi
Karsten Jakobsen Bent
Brigitte Vuidepot Annelise
Original Assignee
Immunocore Ltd *
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40834242&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX340168(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Immunocore Ltd * filed Critical Immunocore Ltd *
Publication of MX2011012184A publication Critical patent/MX2011012184A/es
Publication of MX340168B publication Critical patent/MX340168B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001136—Cytokines
    • A61K39/00114—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La presente invención se refiere a un polipéptido bifuncional que comprende un asociado de unión específico para un péptido-epítopo MHC, tal como un anticuerpo o un receptor de célula T ("TCR"), y un efector inmunitario, tal como un anticuerpo o una citocina, la parte efectora inmunitaria estando enlazada a N-terminal de la parte del péptido-MHC.
MX2011012184A 2009-05-20 2010-05-19 Polipeptidos bifuncionales. MX340168B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0908613.3A GB0908613D0 (en) 2009-05-20 2009-05-20 T Cell Reseptors
PCT/GB2010/000988 WO2010133828A1 (en) 2009-05-20 2010-05-19 Bifunctional polypeptides

Publications (2)

Publication Number Publication Date
MX2011012184A MX2011012184A (es) 2012-03-26
MX340168B true MX340168B (es) 2016-06-29

Family

ID=40834242

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011012184A MX340168B (es) 2009-05-20 2010-05-19 Polipeptidos bifuncionales.

Country Status (22)

Country Link
US (6) US10130721B2 (es)
EP (3) EP2432802B1 (es)
JP (4) JP5667171B2 (es)
CN (1) CN102439034B (es)
AU (1) AU2010250951B2 (es)
BR (1) BRPI1013029A2 (es)
CA (2) CA2968393C (es)
CY (3) CY1118405T1 (es)
DK (3) DK3112376T3 (es)
EA (1) EA020841B1 (es)
ES (3) ES2608653T3 (es)
GB (1) GB0908613D0 (es)
HR (3) HRP20170086T1 (es)
HU (3) HUE038342T2 (es)
LT (3) LT3112377T (es)
MX (1) MX340168B (es)
PL (3) PL3112376T3 (es)
PT (3) PT3112376T (es)
SI (3) SI3112377T1 (es)
SM (3) SMT201700067T1 (es)
TR (2) TR201905437T4 (es)
WO (1) WO2010133828A1 (es)

Families Citing this family (108)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
CA2824515C (en) 2011-01-18 2022-09-13 Bioniz, Llc Compositions and methods for modulating gamma-c-cytokine activity
EP3392270B1 (en) * 2011-09-15 2020-08-26 The United States of America, as Represented by the Secretary Department of Health and Human Services T cell receptors recognizing hla-a1- or hla-cw7-restricted mage
EP2760892A1 (en) * 2011-09-29 2014-08-06 Apo-T B.V. Multi-specific binding molecules targeting aberrant cells
US8524234B2 (en) 2011-11-03 2013-09-03 Tolera Therapeutics, Inc Antibody for selective inhibition of T-cell responses
US20130273089A1 (en) 2011-11-03 2013-10-17 Tolera Therapeutics, Inc. Antibody and methods for selective inhibition of t-cell responses
SG11201404007WA (en) 2012-01-13 2014-08-28 Apo T B V Aberrant cell-restricted immunoglobulins provided with a toxic moiety
GB201223172D0 (en) 2012-12-21 2013-02-06 Immunocore Ltd Method
GB201313377D0 (en) * 2013-07-26 2013-09-11 Adaptimmune Ltd T cell receptors
US9959384B2 (en) 2013-12-10 2018-05-01 Bioniz, Llc Methods of developing selective peptide antagonists
BR112016021004A2 (pt) 2014-03-14 2018-01-23 Immunocore Limited biblioteca de partículas; receptor de células t (tcr) isolado não natural; uso de uma biblioteca; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; ácido nucleico; método de construção de uma biblioteca de partículas; método de obtenção de um receptor de células t que se liga especificamente a um antígeno de peptídeo; e partícula
WO2016014725A1 (en) 2014-07-22 2016-01-28 The University Of Notre Dame Du Lac Molecular constructs and uses thereof
EP3216801B1 (en) 2014-11-07 2020-01-01 Guangdong Xiangxue Life Sciences, Ltd. Soluble heterodimeric t cell receptor, and preparation method and use thereof
GB201516274D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516270D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516277D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR libraries
GB201516272D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516265D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516275D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
GB201516269D0 (en) 2015-09-15 2015-10-28 Adaptimmune Ltd And Immunocore Ltd TCR Libraries
PT3359556T (pt) 2015-10-09 2021-08-30 Bioniz Llc Modulação da atividade de citocinas gama-c
GB201520567D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520568D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd Peptides
GB201520575D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
WO2017089786A1 (en) 2015-11-23 2017-06-01 Immunocore Limited Peptides
GB201607534D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520563D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520592D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520597D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520541D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520548D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520589D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520559D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520557D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520566D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520562D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520603D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520595D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520546D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520545D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520539D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520543D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520583D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520550D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520565D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201604468D0 (en) 2016-03-16 2016-04-27 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520570D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201607535D0 (en) 2016-04-29 2016-06-15 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520542D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520544D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520564D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520558D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520579D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201520536D0 (en) 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides
GB201522592D0 (en) * 2015-12-22 2016-02-03 Immunocore Ltd T cell receptors
DK3430037T3 (da) * 2016-03-16 2022-11-21 Immatics Biotechnologies Gmbh Transficerede t-celler og t-cellereceptorer til anvendelse i immunterapi mod cancere
GB201604953D0 (en) 2016-03-23 2016-05-04 Immunocore Ltd T cell receptors
ES2914648T3 (es) 2016-04-08 2022-06-15 Immunocore Ltd Receptores de células T
WO2017192536A1 (en) 2016-05-02 2017-11-09 University Of Kansas Eliminating mhc restriction from the t cell receptor as a strategy for immunotherapy
PT3464380T (pt) 2016-06-02 2025-02-06 Immunocore Ltd Regime de dosagem para proteína de fusão de tcr específico de gp100 - scfv anti-cd3
EP3532078A4 (en) * 2016-10-31 2020-06-03 H. Lee Moffitt Cancer Center And Research Institute, Inc. ARTIFICIAL ANTI-PRESENTING CELLS FOR THE EXPANSION OF IMMUNE CELLS FOR IMMUNOTHERAPY
EP3535288A1 (en) 2016-11-07 2019-09-11 Immunocore Limited Peptides
CN108203459A (zh) * 2016-12-19 2018-06-26 广东香雪精准医疗技术有限公司 源自于prame的肿瘤抗原短肽
GB201709866D0 (en) 2017-06-20 2017-08-02 Immunocore Ltd T cell receptors
JP2021522835A (ja) 2018-05-14 2021-09-02 イムノコア リミテッド 二機能性結合ポリペプチド
GB201815041D0 (en) 2018-09-14 2018-10-31 Scancell Ltd Epitopes
CA3126422A1 (en) * 2019-01-14 2020-07-23 Nanjing Legend Biotech Co., Ltd. Chimeric receptor polypeptides and uses thereof
HUE065436T2 (hu) 2019-01-17 2024-06-28 Immunocore Ltd Kiszerelések
GB201901306D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Multi-domain binding molecules
GB201901305D0 (en) * 2019-01-30 2019-03-20 Immunocore Ltd Specific binding molecules
EP3921443A1 (en) 2019-02-08 2021-12-15 F. Hoffmann-La Roche AG Diagnostic and therapeutic methods for cancer
GB201902277D0 (en) 2019-02-19 2019-04-03 King S College London Therapeutic agents
CN113811549A (zh) 2019-02-21 2021-12-17 Xencor股份有限公司 非靶向和靶向性il-10 fc融合蛋白
AU2020243431B2 (en) 2019-03-18 2025-12-18 Ludwig Institute For Cancer Research Ltd. A2/NY-ESO-1 specific T cell receptors and uses thereof
GB201904328D0 (en) 2019-03-28 2019-05-15 Immunocore Ltd Specific binding molecules
BR112021021878A2 (pt) 2019-05-03 2022-01-18 Bioniz Llc Modulação dos efeitos de sinalização da gama-c-citocina para tratamento da alopecia e distúrbios associados
GB201915282D0 (en) 2019-10-22 2019-12-04 Immunocore Ltd Specific binding molecules
GB202005779D0 (en) 2020-04-21 2020-06-03 Scancell Ltd Anti-tumour immune responses
GB202006629D0 (en) 2020-05-05 2020-06-17 Immunocore Ltd Specific binding molecules
GB202010329D0 (en) 2020-07-06 2020-08-19 Immunocore Ltd Specific binding molecules
EP4196612A1 (en) 2020-08-12 2023-06-21 Genentech, Inc. Diagnostic and therapeutic methods for cancer
CN112239495B (zh) * 2020-10-29 2022-04-12 上海药明生物技术有限公司 稳定的tcr结构及应用
WO2022184805A1 (en) 2021-03-03 2022-09-09 Immatics Biotechnologies Gmbh Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
IL308258A (en) 2021-05-05 2024-01-01 Immatics Biotechnologies Gmbh Bma031 antigen binding polypeptides
EP4113120A1 (en) 2021-06-28 2023-01-04 Immatics Biotechnologies GmbH Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20230024554A1 (en) 2021-06-28 2023-01-26 Immatics Biotechnologies Gmbh Method of characterizing the binding characteristics between a peptide of interest and mhc molecules
US20240327491A1 (en) 2021-07-12 2024-10-03 Ludwig Institute For Cancer Research Ltd T cell receptors specific for tumor-associated antigens and methods of use thereof
CN117964777A (zh) * 2021-08-26 2024-05-03 瑅安生物医药（杭州）有限公司 一种接近天然分子的多肽融合分子
EP4198052A1 (en) 2021-12-15 2023-06-21 Eberhard Karls Universität Tübingen Medizinische Fakultät Peptides and antigen binding proteins for use in immunotherapy against fibrolamellar hepatocellular carcinoma (fl-hcc) and other cancers
WO2023156663A1 (en) 2022-02-20 2023-08-24 Immunocore Limited Hiv-specific binding molecules and tcr
TW202423994A (zh) 2022-08-18 2024-06-16 英商英美偌科有限公司 多域結合分子
TW202417476A (zh) 2022-08-18 2024-05-01 英商英美偌科有限公司 Ｔ細胞受體及其融合蛋白
EP4573124A1 (en) 2022-08-18 2025-06-25 Immunocore Limited Multi-domain binding molecules
IL318933A (en) 2022-08-18 2025-04-01 Immunocore Ltd Multi-functional binding molecules
WO2024067821A1 (zh) * 2022-09-30 2024-04-04 瑅安生物医药（杭州）有限公司 一种修饰细胞及其用途
AU2023395989A1 (en) 2022-12-16 2025-07-24 Repertoire Immune Medicines, Inc. T cell receptors binding hpv-16 epitopes
EP4646268A1 (en) 2023-01-06 2025-11-12 Immunocore Limited Binding molecules against a piwil1 peptide-hla complex
WO2024146951A1 (en) 2023-01-06 2024-07-11 Immunocore Limited Binding molecules against a prame peptide-hla complex
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
WO2025087436A1 (zh) * 2023-10-27 2025-05-01 北京可瑞生物科技有限公司 基于t细胞受体的多特异性多肽分子及其组合物和用途
GB202320012D0 (en) 2023-12-22 2024-02-07 Immunocore Ltd Bispecific molecules
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies
US12240900B1 (en) 2024-02-02 2025-03-04 Medicovestor, Inc. Nucleic acids, vectors, and cells that encode antibodies and other proteins that bind folate receptor alpha
US12378314B1 (en) 2024-02-02 2025-08-05 Medicovestor, Inc. Proteins that bind folate receptor alpha including fully-human antibodies
US12258396B1 (en) 2024-02-02 2025-03-25 Medicovestor, Inc. Methods of using immunotherapeutics that bind folate receptor alpha
GB202406837D0 (en) 2024-05-14 2024-06-26 Immunocore Ltd Screening methods
GB2641580A (en) 2024-06-07 2025-12-10 T Therapeutics Ltd Tumour-transforming multispecific proteins

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0940468A1 (en) * 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
AU758949B2 (en) * 1998-05-19 2003-04-03 Avidex Limited Multivalent T cell receptor complexes
DE69936927T2 (de) * 1998-10-21 2008-05-15 Altor Bioscience Corp., Miramar Polyspezifische bindemoleküle und deren verwendung
CN1430728A (zh) 2000-05-25 2003-07-16 苏诺尔分子公司 T细胞受体交互作用的调节
US20030144474A1 (en) * 2000-06-05 2003-07-31 Sunol Molecular Corporation T cell receptor fusions and conjugates and methods of use thereof
US20030017134A1 (en) * 2001-06-19 2003-01-23 Technion Research And Development Foundation Ltd. Methods and pharmaceutical compositions for immune deception, particularly useful in the treatment of cancer
EP1421115B1 (en) * 2001-08-31 2005-03-02 Avidex Limited Soluble t cell receptor
US20030223994A1 (en) 2002-02-20 2003-12-04 Hoogenboom Henricus Renerus Jacobus Mattheus MHC-peptide complex binding ligands
NZ539225A (en) 2002-10-09 2006-09-29 Avidex Ltd Single chain recombinant T cell receptors
GB0304068D0 (en) 2003-02-22 2003-03-26 Avidex Ltd Substances
JP4773434B2 (ja) * 2004-05-19 2011-09-14 イムノコア リミテッド 高親和性ｎｙ−ｅｓｏｔ細胞受容体
US20090042285A1 (en) 2004-05-27 2009-02-12 Weidanz Jon A Antibodies at T cell receptor mimics, methods of production and uses thereof
US20060034850A1 (en) 2004-05-27 2006-02-16 Weidanz Jon A Antibodies as T cell receptor mimics, methods of production and uses thereof
CA2570458C (en) * 2004-06-09 2014-05-20 Technion Research & Development Foundation Ltd. Antibodies for selective apoptosis of cells
MX2007003910A (es) * 2004-10-01 2007-06-07 Avidex Ltd Receptores de celulas t que contienen un enlace entre cadenas bisulfuro no nativo ligado a agentes terapeuticos.
WO2007071426A1 (en) * 2005-12-21 2007-06-28 Micromet Ag Pharmaceutical compositions with resistance to soluble cea
RU2008129827A (ru) * 2005-12-21 2010-01-27 МЕДИММЬЮН, ЭлЭлСи (US) МОЛЕКУЛЫ EphA2-BiTE И ИХ ПРИМЕНЕНИЕ
GB0708585D0 (en) 2007-05-03 2007-06-13 Queen Mary & Westfield College Novel antibody and use in diagnosis and therapy of arthropathies
GB0816096D0 (en) 2008-09-04 2008-10-15 Medigene Ltd Diabetes t cell receptors
GB0908613D0 (en) * 2009-05-20 2009-06-24 Immunocore Ltd T Cell Reseptors
GB0911566D0 (en) * 2009-07-03 2009-08-12 Immunocore Ltd T cell receptors

Also Published As

Publication number Publication date
DK3112377T3 (en) 2018-07-30
SI3112376T1 (sl) 2019-08-30
EP3112376A2 (en) 2017-01-04
AU2010250951B2 (en) 2015-04-30
HUE032929T2 (hu) 2017-11-28
JP2019172678A (ja) 2019-10-10
US10130721B2 (en) 2018-11-20
US20190231896A1 (en) 2019-08-01
EA201101660A8 (ru) 2014-09-30
HRP20190674T1 (hr) 2019-08-09
US20230241238A1 (en) 2023-08-03
PL3112376T3 (pl) 2019-07-31
SI2432802T1 (sl) 2017-01-31
US10576162B2 (en) 2020-03-03
SI3112377T1 (en) 2018-06-29
EP3112377B1 (en) 2018-04-18
PL3112377T3 (pl) 2018-10-31
LT3112376T (lt) 2019-05-10
CA2762604A1 (en) 2010-11-25
EP2432802B1 (en) 2016-11-02
ES2721058T3 (es) 2019-07-26
JP2015096527A (ja) 2015-05-21
HUE038342T2 (hu) 2018-10-29
JP5667171B2 (ja) 2015-02-12
HRP20170086T1 (hr) 2017-06-02
US20120190828A1 (en) 2012-07-26
TR201809945T4 (tr) 2018-08-27
LT3112377T (lt) 2018-05-25
JP2012527439A (ja) 2012-11-08
GB0908613D0 (en) 2009-06-24
SMT201700067T1 (it) 2017-05-08
CN102439034B (zh) 2015-01-28
EP3112376A3 (en) 2017-03-29
CY1121558T1 (el) 2020-05-29
EP3112376B1 (en) 2019-01-23
CA2968393C (en) 2019-07-23
CA2968393A1 (en) 2010-11-25
BRPI1013029A2 (pt) 2016-04-05
US20190231895A1 (en) 2019-08-01
US20190247512A1 (en) 2019-08-15
PT3112376T (pt) 2019-05-20
HRP20180757T1 (hr) 2018-07-27
CY1118405T1 (el) 2017-06-28
SMT201900232T1 (it) 2019-05-10
PT3112377T (pt) 2018-07-13
AU2010250951A1 (en) 2011-12-08
MX2011012184A (es) 2012-03-26
US10420846B2 (en) 2019-09-24
EP3112377A1 (en) 2017-01-04
CY1120439T1 (el) 2019-07-10
PL2432802T3 (pl) 2017-07-31
CN102439034A (zh) 2012-05-02
TR201905437T4 (tr) 2019-05-21
CA2762604C (en) 2018-01-16
US10517960B2 (en) 2019-12-31
EA020841B1 (ru) 2015-02-27
SMT201800364T1 (it) 2018-09-13
HUE043245T2 (hu) 2019-08-28
EA201101660A1 (ru) 2012-05-30
US20190275165A1 (en) 2019-09-12
ES2672095T3 (es) 2018-06-12
EP2432802A1 (en) 2012-03-28
ES2608653T3 (es) 2017-04-12
WO2010133828A1 (en) 2010-11-25
PT2432802T (pt) 2017-02-13
LT2432802T (lt) 2017-01-10
JP2017110019A (ja) 2017-06-22
DK2432802T3 (en) 2017-02-13
DK3112376T3 (en) 2019-04-29

Similar Documents

Publication Publication Date Title
MX2011012184A (es) Polipeptidos bifuncionales.
EP3970746A3 (en) Polypeptide variants and uses thereof
NZ607224A (en) Non-lipidated variants of neisseria meningitidis orf2086 antigens
MX2012009175A (es) Metodos para identificar y aislar celulas que expresan un polipeptido.
AU2018260863A1 (en) Human IgG1 Fc region variants and uses thereof
MX341309B (es) Anticuerpos especificos del heterodimero de anti-il-23.
EP4364754A3 (en) Anti-b7-h3 antibodies and antibody drug conjugates
MX341925B (es) Anticuerpos con funcion efectora suprimida o mejorada.
WO2007041635A3 (en) Fc variants with optimized fc receptor binding properties
WO2009130618A3 (en) Flagellin polypeptide vaccines
WO2007136892A3 (en) Engineered antibody-stress protein fusions
NZ602220A (en) Antibodies with ph dependent antigen binding
IL200129A (en) Epitopic preparations of T cells that suppress the immune system
WO2008113005A3 (en) Methods to improve the stability of cellular adhesive proteins and peptides
SG10201808523RA (en) Il-22 polypeptides and il-22 fc fusion proteins and methods of use
NZ612161A (en) Radiolabled her2 binding peptides
IL214779A (en) Isolated monoclonal antibody or epitope-binding antibody on cadm1, methods of preparation and use for drug preparation
WO2008138536A3 (en) Antibody directed to g protein coupled receptors (gpcr)
WO2011137243A3 (en) Fluorescent fusion polypeptides and methods of use
MX2009007572A (es) Proteinas de fusion que contienen los antigenos de rechazo de tumor ny-eso-1 y.
WO2007131210A3 (en) T-cell vaccine
JOP20230223A1 (ar) بولي ببتيد ربط gucy2c واستخداماته
WO2010034825A3 (en) Novel antibodies recognizing native annexin a3
MX2015004892A (es) Metodos y composiciones que se relacionan con anticuerpos de receptor anti-il-21.
UA100692C2 (ru) Днк-плазмиды, имеющие повышенную экспрессию и стабильность

Legal Events

Date Code Title Description
FG Grant or registration